Inpatient Steroids in COPD
From *Open Evidence* and *GOLD*

The recommended regimen for systemic corticosteroids in hospitalized COPD exacerbations is **prednisone 40 mg (or equivalent) orally once daily for 5 days**, with **oral administration preferred** over intravenous when gastrointestinal access is intact. This is consistent across major society guidelines. Below is a summary of each guideline's specific recommendations.

GOLD 2026 Guidelines (Global Initiative for Chronic Obstructive Lung Disease)

The 2026 GOLD Report recommends **40 mg prednisone-equivalent per day for 5 days** (Evidence A) for moderate/severe exacerbations. [1] Key points include:

- **Oral prednisolone is equally effective to intravenous administration**. [1]
- Nebulized budesonide alone may be a suitable alternative in some patients, providing similar benefits to IV methylprednisolone. [1]
- **Longer courses of oral glucocorticoids are associated with increased risk of pneumonia and mortality**. [1]
- **Even short bursts carry subsequent increased risk of pneumonia, sepsis, and death; use should be confined to patients with significant exacerbations**. [1]
- Emerging evidence suggests corticosteroids may be more efficacious in patients with **elevated blood eosinophil levels**, and the STARR2 trial suggested prednisone could be safely avoided in patients with low eosinophils in primary care settings, though further validation in hospitalized patients is needed. [1]

ERS/ATS 2017 Guidelines (European Respiratory Society / American Thoracic Society)

The ERS/ATS guideline provides the following recommendations: [2]

- For hospitalized patients: **oral corticosteroids are suggested rather than intravenous corticosteroids** if gastrointestinal access and function are intact (conditional recommendation, low quality of evidence).
- For ambulatory patients: a short course (≤14 days) of oral corticosteroids is suggested (conditional recommendation, very low quality of evidence).

- Pooled data from two RCTs (250 patients) showed **no significant differences** in treatment failure, mortality, readmissions, or length of stay between IV and oral routes, but IV therapy was associated with increased mild adverse effects. [2]

NICE Guidelines

The NICE guidelines recommend oral corticosteroids in conjunction with other therapies in **all patients admitted to hospital** with a COPD exacerbation, with a recommended dose of **30 mg prednisolone daily for 7–14 days**. [2-3] This represents a slightly longer duration than the current GOLD recommendation.

Summary Comparison Table

Guideline	Dose	Duration	Route	References
GOLD 2026	40 mg prednisone-equivalent/day	5 days	Oral preferred (equally effective to IV)	[1]
ERS/ATS 2017	Not specified (defers to GOLD)	≤14 days (ambulatory); not specified for inpatient	Oral preferred over IV if GI access intact	[2]
NICE 2010	30 mg prednisolone/day	7–14 days	Oral	[2-3]

Key Supporting Evidence

The **REDUCE trial** (2013) was the pivotal noninferiority RCT that established the 5-day regimen. It randomized 314 patients (92% hospitalized) to 40 mg prednisone daily for 5 days versus 14 days. The 5-day course was noninferior for time to next exacerbation within 180 days (HR 0.95, 90% CI 0.70–1.29), with significantly lower cumulative glucocorticoid exposure (379 mg vs 793 mg, $p < 0.001$). [4]

In patients presenting to the emergency department with acute exacerbations of COPD, 5-day treatment with systemic glucocorticoids was noninferior to 14-day treatment with regard to reexacerbation within 6 months of follow-up but significantly reduced glucocorticoid exposure.

— **Jörg D. Leuppi, MD, PhD**, *et al.* Short-term vs Conventional Glucocorticoid Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease: The REDUCE Randomized Clinical Trial. JAMA. June 4, 2013.

The following Kaplan-Meier curve from the REDUCE trial demonstrates the near-identical reexacerbation-free survival between the 5-day and 14-day treatment groups:



Figure 2. Time to Reexacerbation of Chronic Obstructive Pulmonary Disease

Short-term vs Conventional Glucocorticoid Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease: The REDUCE Randomized Clinical Trial. JAMA. June 4, 2013.

A Cochrane systematic review (2018) of 8 studies with 582 participants confirmed that shorter courses (~5 days) showed no difference in treatment failure, relapse, adverse events, hospital length of stay, or lung function recovery compared to longer courses (10–14 days). [3] A more recent meta-analysis (2023) including both RCTs and cohort studies (11,532 participants) similarly supported that short-duration treatment is not worse than long-duration treatment. [5]

Practical Considerations

- No taper is needed for a 5-day course. [6]
- IV corticosteroids should be reserved for patients who are **unable to swallow, are vomiting, or require mechanical ventilation**. [7]
- Blood glucose monitoring is warranted given the risk of hyperglycemia even with short courses. [3]

Would you like to explore the emerging evidence on eosinophil-guided corticosteroid therapy for COPD exacerbations and how blood eosinophil thresholds might be used to identify patients who can safely forgo systemic steroids?

1. 2026 GOLD Report and Pocket Guide: Global Strategy for Prevention, Diagnosis, and Management of COPD – 2026 Report. Global Initiative for Chronic Obstructive Lung Disease. 2025. Guideline

2. Management of COPD Exacerbations: A European Respiratory Society/American Thoracic Society Guideline. The European Respiratory Journal. 2017. Wedzicha JA, Miravitlles M, Hurst JR, et al.Guideline

3. Different Durations of Corticosteroid Therapy for Exacerbations of Chronic Obstructive Pulmonary Disease. The Cochrane Database of Systematic Reviews. 2018. Walters JA, Tan DJ, White CJ, Wood-Baker R.SR

4. Short-term vs Conventional Glucocorticoid Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease: The REDUCE Randomized Clinical Trial. The Journal of the American Medical Association. 2013. Leuppi JD, Schuetz P, Bingisser R, et al.RCT

5. Long- Versus Short-Duration Systemic Corticosteroid Regimens for Acute Exacerbations of COPD: A Systematic Review and Meta-Analysis of Randomized Trials and Cohort Studies. PloS One. 2024. Zhao Z, Lou O, Wang Y, et al.

6. Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease. The New England Journal of Medicine. 2019. Celli BR, Wedzicha JA.Review

7. Glucocorticoid Treatment in Severe COPD Exacerbations: Biological Rationale, Clinical Effects, and Practical Advice. Seminars in Respiratory and Critical Care Medicine. 2025. Sartori F, Sartori G, Di Chiara C, Fantin A, Crisafulli E.New

Practice Guidelines

The **American College of Chest Physicians (CHEST) and Canadian Thoracic Society** recommend systemic corticosteroids for treating acute exacerbations of COPD but note that long-term systemic oral corticosteroids are not recommended. [1] The guideline highlights that when comparing different corticosteroid regimens (e.g., hydrocortisone vs. methylprednisolone), no difference in readmission rates was found, and higher-dose or longer-duration regimens did not demonstrate superiority in preventing subsequent exacerbations. [1] Notably, the Niewoehner et al. trial randomized hospitalized patients to 8 weeks vs. 2 weeks of corticosteroids vs. placebo and found no difference in 6-month hospitalization rates between groups (OR 1.07; 95% CI 0.49–2.36), suggesting that prolonged high-dose exposure confers no additional benefit in preventing readmissions. [1]

American College of Chest Physicians (CHEST) Prevention of Acute Exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Criner GJ, Bourbeau J, Diekemper RL, et al. Chest. 2015;147(4):894-942. doi:10.1378/chest.14-1676.

Using doses substantially higher than the GOLD-recommended **40 mg prednisone-equivalent daily** raises several well-documented and presumed concerns, with **no convincing evidence of improved efficacy** to justify the added risk.

1. No Incremental Efficacy with Higher Doses

A meta-analysis and indirect treatment comparison (12 RCTs, 1,375 participants) categorized corticosteroid doses as low (≤40 mg prednisone-equivalent/day), medium (40–100 mg), and high (>100 mg). The indirect comparison found **no significant differences** in treatment failure or FEV_1 improvement between low-, medium-, and high-dose groups, concluding that low-dose corticosteroids were sufficient and noninferior to higher doses. [2] The ERS/ATS guideline similarly noted that high-dose IV corticosteroids "may not have a higher efficacy than oral corticosteroids and can potentially be associated with a higher risk of adverse events." [3]

2. Hyperglycemia

This is the most consistently documented dose-dependent adverse effect. The same meta-analysis found that **only the high-dose group** (>100 mg prednisone-equivalent/day) had a statistically significant increase in hyperglycemia compared to placebo (RR 2.52; 95% CI 1.13–5.62), whereas the low-dose group did not. [2] A Cochrane review confirmed that one extra patient develops hyperglycemia for every seven treated with systemic corticosteroids (OR 2.79; 95% CI 1.86–4.19). [4] A systematic review of glucocorticoid-induced hyperglycemia in COPD found a pooled prevalence of **38.6%** and a 2.4-fold increased risk of new-onset hyperglycemia with systemic corticosteroid use. [5] Importantly, patients who develop steroid-induced hyperglycemia during hospitalization may have a **37-fold higher risk** of developing impaired glucose tolerance or type 2 diabetes within one year. [6]

3. Infection Risk: Pneumonia and Sepsis

The GOLD 2026 Report warns that even short bursts of glucocorticoids are associated with increased risk of **pneumonia, sepsis, and death**, and longer courses further increase pneumonia and mortality risk. [7] A large Canadian cohort study (163,514 COPD patients) found that current oral corticosteroid use was associated with a **66% increase in sepsis risk** (RR 1.66; 95% CI 1.35–2.05), with the risk persisting for approximately 5 months after exposure. [8] Higher cumulative doses would be expected to amplify this risk.

4. Steroid Myopathy and Respiratory Muscle Weakness

This is a particularly concerning complication in COPD patients who already have compromised respiratory mechanics. The GOLD 2026 Report identifies **steroid myopathy** as a key side effect that can contribute to muscle weakness, decreased functionality, and respiratory failure. [7] Two distinct patterns are recognized: [9]

- **Acute myopathy**: Occurs after short-term treatment with high doses, causing generalized muscle atrophy and rhabdomyolysis, including respiratory muscles.
- **Chronic myopathy**: Occurs with prolonged moderate doses, causing gradual proximal limb weakness and reduced respiratory muscle force.

A study of COPD patients with steroid-induced myopathy demonstrated severe reductions in maximal inspiratory pressure (PImax 37% vs. 67% predicted) and maximal expiratory pressure (PEmax 34% vs. 74% predicted) compared to matched COPD controls, with **reduced survival** in the myopathy group. [10]

5. Adrenal Suppression

Higher cumulative corticosteroid exposure increases the risk of hypothalamic-pituitary-adrenal (HPA) axis suppression, which is particularly relevant in COPD patients who experience frequent exacerbations and thus repeated steroid courses. [11] The risk of adverse drug effects rises with increasing frequency of high-dose use and with **cumulative exposure exceeding 1 gram** of prednisone-equivalent. [11]

6. Other Dose-Dependent Concerns

Additional documented or presumed risks that escalate with higher doses include:

- **Osteoporosis and fractures** — particularly important given the high baseline rate of vertebral compression fractures in the COPD population [11]
- **Fluid retention and hypertension** [11]
- **Psychiatric effects** — insomnia, anxiety, delirium (a non-significant but 2-fold increase was observed vs. placebo) [4]
- **Weight gain** [4]
- **GI effects** — though GI bleeding risk was not significantly increased in ICU-based studies [4]

7. Diminished Benefit in the Most Critically Ill

A meta-analysis of ICU patients with severe COPD exacerbations found that corticosteroids (often given at higher doses in this setting) showed **no significant benefit** in the most severe subgroup (OR 1.12; 95% CI 0.53–2.36), while still increasing glycemic disorders. [12] This raises the concern that escalating doses in the sickest patients may increase harm without proportional benefit.

Summary

The evidence consistently supports that **low-dose corticosteroids (≤40 mg prednisone-equivalent/day) are noninferior to higher doses** for efficacy outcomes in COPD exacerbations, while higher doses carry a dose-dependent increase in hyperglycemia, infection risk, myopathy, adrenal suppression, and skeletal complications. [2][13] The one notable exception is a single RCT suggesting that personalized higher dosing (>60 mg) may reduce in-hospital treatment failure in select patients, though adverse event rates were similar between groups. [14] This finding requires further validation before changing standard practice.

Would you like to explore the evidence on eosinophil-guided corticosteroid prescribing as a strategy to avoid unnecessary steroid exposure altogether in certain COPD exacerbation phenotypes?

1. Prevention of Acute Exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015. Criner GJ, Bourbeau J, Diekemper RL, et al.Guideline

2. Efficacy and Safety of Different Doses of Systemic Corticosteroids in COPD Exacerbation. Respiratory Care. 2021. Pu X, Liu L, Feng B, et al.SR

3. Management of COPD Exacerbations: A European Respiratory Society/American Thoracic Society Guideline. The European Respiratory Journal. 2017. Wedzicha JA, Miravitlles M, Hurst JR, et al.Guideline

4. Systemic Corticosteroids for Acute Exacerbations of Chronic Obstructive Pulmonary Disease. The Cochrane Database of Systematic Reviews. 2014. Walters JA, Tan DJ, White CJ, et al.SR

5. Glucocorticoid Treatment and New-Onset Hyperglycaemia and Diabetes in People Living With Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. Diabetic Medicine : A Journal of the British Diabetic Association. 2025. Golubic R, Mumbole H, Ismail MH, et al.SR

6. Risk of Future Type 2 Diabetes Mellitus in Patients Developing Steroid-Induced Hyperglycemia During Hospitalization for Chronic Obstructive Pulmonary Disease Exacerbation. Lung. 2020. Upadhyay J, Trivedi N, Lal A.

7. 2026 GOLD Report and Pocket Guide: Global Strategy for Prevention, Diagnosis, and Management of COPD – 2026 Report. Global Initiative for Chronic Obstructive Lung Disease. 2025. Guideline

8. The Risk of Sepsis With Inhaled and Oral Corticosteroids in Patients With COPD. Copd. 2017. Ernst P, Coulombe J, Brassard P, Suissa S.

9. Steroid-Induced Myopathy and Its Significance to Respiratory Disease: A Known Disease Rediscovered. The European Respiratory Journal. 1992. Dekhuijzen PN, Decramer M.Review

10. Functional and Histologic Picture of Steroid-Induced Myopathy in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 1996. Decramer M, de Bock V, Dom R.

11. Different Durations of Corticosteroid Therapy for Exacerbations of Chronic Obstructive Pulmonary Disease. The Cochrane Database of Systematic Reviews. 2018. Walters JA, Tan DJ, White CJ, Wood-Baker R.SR

12. Corticosteroids for Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease in Intensive Care: From the French OUTCOMEREA Cohort. PloS One. 2023. Galerneau LM, Bailly S, Terzi N, et al.

13. Glucocorticoid Treatment in Severe COPD Exacerbations: Biological Rationale, Clinical Effects, and Practical Advice. Seminars in Respiratory and Critical Care Medicine. 2025. Sartori F, Sartori G, Di Chiara C, Fantin A, Crisafulli E.

14. Personalized Variable Vs Fixed-Dose Systemic Corticosteroid Therapy in Hospitalized Patients With Acute Exacerbations of COPD: A Prospective, Multicenter, Randomized, Open-Label Clinical Trial. Chest. 2021. Li L, Zhao N, Ma X, et al.RCT